Trial Profile
PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2023
Price :
$35
*
At a glance
- Drugs Parathyroid hormone (Primary) ; Calcium supplements; Vitamin D
- Indications Hypoparathyroidism
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms PARADIGHM
- Sponsors Shire; Takeda
- 03 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2022 Planned number of patients changed from 900 to 1064.
- 21 Nov 2018 Planned End Date changed from 30 Jun 2035 to 30 Nov 2034.